Patents by Inventor Michael Eric Bigler

Michael Eric Bigler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibody that binds to human programmed death ligand 2 (PD-L2) and uses thereof
    Patent number: 10647771
    Abstract: The present disclosure provides antibodies and antigen binding fragments thereof including, but not limited to, monoclonal antibodies that specifically bind to human programmed death ligand 2 (PD-L2). The invention further provides nucleic acids encoding the antibodies and antigen binding fragments of the invention and host cells transformed therewith. The antibodies and antigen binding proteins of the invention are useful in methods for the immunohistochemical detection of human PD-L2 expression in tissue samples.
    Type: Grant
    Filed: September 20, 2016
    Date of Patent: May 12, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jennifer H. Yearley, Linda Liang, Michael Eric Bigler, Christopher John Gibson
  • ANTIBODY THAT BINDS TO HUMAN PROGRAMMED DEATH LIGAND 2 (PD-L2) AND USES THEREOF
    Publication number: 20180258171
    Abstract: The present disclosure provides antibodies and antigen binding fragments thereof including, but not limited to, monoclonal antibodies that specifically bind to human programmed death ligand 2 (PD-L2). The invention further provides nucleic acids encoding the antibodies and antigen binding fragments of the invention and host cells transformed therewith. The antibodies and antigen binding proteins of the invention are useful in methods for the immunohistochemical detection of human PD-L2 expression in tissue samples.
    Type: Application
    Filed: September 20, 2016
    Publication date: September 13, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Jennifer H. Yearley, Linda Liang, Michael Eric Bigler, Christopher John Gibson
  • Use of bispecific antibodies to regulate immune responses
    Patent number: 8236309
    Abstract: The invention relates generally to the field of immunology, in particular, to bispecific antibodies. Methods for designing a bispecific antibody for use in treating diseases relating to the immune system are disclosed. Specific examples relate to bispecific antibodies which recognize an activating receptor and an inhibiting receptor.
    Type: Grant
    Filed: May 25, 2010
    Date of Patent: August 7, 2012
    Assignee: Schering Corporation
    Inventors: Michael Eric Bigler, Holly Marie Cherwinski, Joseph H. Phillips
  • USE OF BISPECIFIC ANTIBODIES TO REGULATE IMMUNE RESPONSES
    Publication number: 20100330034
    Abstract: The invention relates generally to the field of immunology, in particular, to bispecific antibodies. Methods for designing a bispecific antibody for use in treating diseases relating to the immune system are disclosed. Specific examples relate to bispecific antibodies which recognize an activating receptor and an inhibiting receptor.
    Type: Application
    Filed: May 25, 2010
    Publication date: December 30, 2010
    Applicant: SCHERING CORPORATION
    Inventors: MICHAEL ERIC BIGLER, HOLLY MARIE CHERWINSKI, JOSEPH H. PHILLIPS
  • Use of bispecific antibodies to regulate immune responses
    Publication number: 20030077282
    Abstract: The invention relates generally to the field of immunology, in particular, to bispecific antibodies. Methods for designing a bispecific antibody for use in treating diseases relating to the immune system are disclosed. Specific examples relate to bispecific antibodies which recognize an activating receptor and an inhibiting receptor.
    Type: Application
    Filed: October 11, 2002
    Publication date: April 24, 2003
    Inventors: Michael Eric Bigler, Holly Marie Cherwinski, Joseph H. Phillips